LY-210825

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameLY-210825
Drug Alias NameLY-210825
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPlasminogen stimulants
TargetsPlasminogen
Therapy Area/IndicationsMyocardial InfarctionCoronary Thrombosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEli Lilly And Company
Active IndicationsN/A
Inactive IndicationsMyocardial InfarctionCoronary Thrombosis

Other Information

ATC CodeN/A
Related LinksN/A